Search results
Results from the WOW.Com Content Network
Drug-induced lupus erythematosus is an autoimmune disorder caused by chronic use of certain drugs. These drugs cause an autoimmune response (the body attacks its own cells) producing symptoms similar to those of systemic lupus erythematosus (SLE). There are 38 known medications to cause DIL but there are three that report the highest number of ...
Drug-induced lupus erythematosus is a (generally) reversible condition that usually occurs in people being treated for a long-term illness. Drug-induced lupus mimics SLE. However, symptoms of drug-induced lupus generally disappear once the medication that triggered the episode is stopped.
Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues. [1] Symptoms of these diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs.
The major challenge to developing a new treatment, according to Choi, is finding ways to administer it without activating aryl hydrocarbon receptors throughout the whole body, which may result in ...
Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells.. Elevated CD22 and other B-cell receptor (BCR) proteins are associated with SLE. "Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system" [6] via a process called trogocytosis. [3]
Belimumab is primarily used in people with systemic lupus erythematosus. When it was introduced in 2011, it was the first new drug approved to treat lupus in 56 years. [8] Sales rose to $31.2 million in the first quarter of 2012. [37] The total cost for the first year of treatment with belimumab is $28,000. [38]
The drug is being tested in patients with the most common form of lupus, systemic lupus erythematosus, where the patient's immune system attacks the body's own tissues and potentially leads to ...
The oral drug, brepocitinib, did not meet the primary study goal of reduction in disease activity at week 52 in patients of SLE, in which the immune system that normally helps protect the body ...